Reviewing Burning Rock Biotech (NASDAQ:BNR) & XTL Biopharmaceuticals (NASDAQ:XTLB)

Burning Rock Biotech (NASDAQ:BNR) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk and analyst recommendations.

Insider & Institutional Ownership

30.0% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Burning Rock Biotech and XTL Biopharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16 million	2.11	-$7.92 million	($0.87)	-17.80
XTL Biopharmaceuticals	$450,000.00	10.72	-$6.97 million	($0.64)	-3.18

XTL Biopharmaceuticals has lower revenue, but higher earnings than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than XTL Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Burning Rock Biotech has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Burning Rock Biotech and XTL Biopharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1	0	0	0	1.00
XTL Biopharmaceuticals	1	0	0	0	1.00

Profitability

This table compares Burning Rock Biotech and XTL Biopharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-13.60%	-12.98%	-8.59%
XTL Biopharmaceuticals	N/A	N/A	N/A

Summary

XTL Biopharmaceuticals beats Burning Rock Biotech on 8 of the 11 factors compared between the two stocks.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.